Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.65 |
| ▸ | ITGA4 | P13612 | 17/20 | 0.65 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.65 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.63 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.63 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18047240 | 1.00 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL7538961 | 0.91 | ITGB1 (0.73) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL18047254 | 0.90 | ITGB1 (0.61) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL18047253 | 0.90 | ITGB1 (0.61) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL7395917 | 0.90 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL7395918 | 0.90 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL181378 | 0.87 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL181376 | 0.87 | ITGB1 (0.65) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL18067863 | 0.86 | ITGB1 (0.55) | ITGB1ITGA4ITGB7ITGA5ITGA2 | |
| SCHEMBL4066390 | 0.86 | L3MBTL1 (0.69) | ITGB1ITGA4ITGB7ITGA5ITGA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268369-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | The Regents of The University of California (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016145258-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | ITGB1, ITGA1, ITGAV | ITGB1 1/4885ITGA4 10/4885ITGB7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.